Pilot Study of Depot NTX in Homeless Veterans

This study has been terminated.
(Poor enrollment)
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT01155869
First received: June 30, 2010
Last updated: June 16, 2014
Last verified: June 2014
Results First Received: September 17, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Health Services Research
Condition: Alcohol Dependence
Interventions: Drug: Depot naltrexone
Drug: Oral Naltrexone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
215 potential subjects were approached over a 16-month period of recruitment; only 15 agreed to be screen after hearing of study procedures.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
5 were excluded (1 did not meet criteria for homelessness, 1 did not meet criteria for alcohol dependence, 1 had untreated delusional thinking, and 2 had opioid-requiring pain); 3 eligible participants did not appear for baseline interview and could not be found; only 7 were randomized.

Reporting Groups
  Description
XR-NTX Depot naltrexone (Vivitrol) 380 mg. IM monthly
Oral Naltrexone Naltrexone 50 mg tablet PO daily

Participant Flow:   Overall Study
    XR-NTX     Oral Naltrexone  
STARTED     3     4  
COMPLETED     0     3  
NOT COMPLETED     3     1  
Lost to Follow-up                 3                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
XR-NTX Depot naltrexone (Vivitrol) 380 mg. IM monthly
Oral Naltrexone Naltrexone 50 mg tablet PO daily
Total Total of all reporting groups

Baseline Measures
    XR-NTX     Oral Naltrexone     Total  
Number of Participants  
[units: participants]
  3     4     7  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     3     4     7  
>=65 years     0     0     0  
Gender  
[units: participants]
     
Female     0     0     0  
Male     3     4     7  
Region of Enrollment  
[units: participants]
     
United States     3     4     7  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Weekly Self-reported Alcohol Consumption   [ Time Frame: 24 weeks ]

2.  Secondary:   Treatment Participation   [ Time Frame: 16 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Only 15 of 215 alcohol-dependent, homeless veterans would consider a study that included an intramuscular injection of XR-NTX. Of 3 given XR-NTX, only 1 returned for injection #2. Aversion to injection likely contributed to poor acceptability.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Peter Friedmann
Organization: Providence VA Medical Center
phone: 401-273-7100 ext 6240
e-mail: peter.friedmann@va.gov


Publications of Results:

Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT01155869     History of Changes
Other Study ID Numbers: PPO 10-079
Study First Received: June 30, 2010
Results First Received: September 17, 2013
Last Updated: June 16, 2014
Health Authority: United States: Federal Government